Clinical TrialJul 2, 2026, 08:07 AM
Tenax to Present Phase 3 LEVEL Trial Data at ESC Congress
AI Summary
Tenax Therapeutics announced it will present results from its Phase 3 LEVEL clinical trial at the European Society of Cardiology (ESC) Congress 2026. The company now anticipates reporting topline data from the trial in August 2026. The LEVEL trial, evaluating TNX-103 for pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF), completed enrollment in March 2026 and is well-powered to detect its primary endpoint.
Key Highlights
- Tenax to present Phase 3 LEVEL clinical trial results at ESC Congress 2026.
- Topline data from the Phase 3 LEVEL clinical trial is now expected in August 2026.
- Presentation titled "Levosimendan in patients with pulmonary hypertension due to heart failure with preserved ejection fraction: results of the LEVEL trial".
- Professor Sanjiv Shah, MD, Northwestern University, will present the data.
- Presentation scheduled for Saturday, August 29, 2026, 11:15-11:30 CEST.
- LEVEL trial (NCT05983250) evaluates TNX-103 (oral levosimendan) for PH-HFpEF.
- Enrollment of over 230 patients was completed in March 2026.
- Trial is powered at over 90% to detect a 25-meter change in 6-minute walk distance (6MWD), the primary endpoint.
Price Impact
More from TENX